These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29605483)

  • 1. Severe opioid withdrawal precipitated by Vivitrol®.
    Wightman RS; Nelson LS; Lee JD; Fox LM; Smith SW
    Am J Emerg Med; 2018 Jun; 36(6):1128.e1-1128.e2. PubMed ID: 29605483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone.
    Fishman M
    Addiction; 2008 Aug; 103(8):1399-401. PubMed ID: 18855831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence.
    Wang AL; Elman I; Lowen SB; Blady SJ; Lynch KG; Hyatt JM; O'Brien CP; Langleben DD
    Transl Psychiatry; 2015 Mar; 5(3):e531. PubMed ID: 25781230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid Withdrawal Precipitated by Long-Acting Antagonists.
    Kunzler NM; Wightman RS; Nelson LS
    J Emerg Med; 2020 Feb; 58(2):245-253. PubMed ID: 32005608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial.
    Collins ED; Kleber HD; Whittington RA; Heitler NE
    JAMA; 2005 Aug; 294(8):903-13. PubMed ID: 16118380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
    Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
    Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haight-Ashbury free clinics' drug detoxification protocols--Part 2: Opioid blockade.
    Galloway G; Hayner G
    J Psychoactive Drugs; 1993; 25(3):251-2. PubMed ID: 8258763
    [No Abstract]   [Full Text] [Related]  

  • 8. Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report.
    Szczesniak LM; Calleo VJ; Sullivan RW
    Harm Reduct J; 2020 Oct; 17(1):71. PubMed ID: 33028340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder.
    Sibai M; Mishlen K; Nunes EV; Levin FR; Mariani JJ; Bisaga A
    Am J Drug Alcohol Abuse; 2020 May; 46(3):289-296. PubMed ID: 31860366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of rapid (opioid) detoxification with clonidine-assisted detoxification for heroin-dependent persons.
    Arnold-Reed DE; Hulse GK
    J Opioid Manag; 2005; 1(1):17-23. PubMed ID: 17315407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-release naltrexone modulates brain response to drug cues in abstinent heroin-dependent patients.
    Langleben DD; Ruparel K; Elman I; Loughead JW; Busch EL; Cornish J; Lynch KG; Nuwayser ES; Childress AR; O'Brien CP
    Addict Biol; 2014 Mar; 19(2):262-71. PubMed ID: 22747521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid opiate detoxication in outpatient treatment: relationship with naltrexone compliance.
    Gerra G; Zaimovic A; Rustichelli P; Fontanesi B; Zambelli U; Timpano M; Bocchi C; Delsignore R
    J Subst Abuse Treat; 2000 Mar; 18(2):185-91. PubMed ID: 10716102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.
    Lee JD; Friedmann PD; Kinlock TW; Nunes EV; Boney TY; Hoskinson RA; Wilson D; McDonald R; Rotrosen J; Gourevitch MN; Gordon M; Fishman M; Chen DT; Bonnie RJ; Cornish JW; Murphy SM; O'Brien CP
    N Engl J Med; 2016 Mar; 374(13):1232-42. PubMed ID: 27028913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Withdrawal syndrome caused by naltrexone in opioid abusers.
    Hassanian-Moghaddam H; Afzali S; Pooya A
    Hum Exp Toxicol; 2014 Jun; 33(6):561-7. PubMed ID: 23690227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methods of detoxification and their role in treating patients with opioid dependence.
    O'Connor PG
    JAMA; 2005 Aug; 294(8):961-3. PubMed ID: 16118388
    [No Abstract]   [Full Text] [Related]  

  • 17. A comparison of antagonist-precipitated withdrawal under anesthesia to standard inpatient withdrawal as a precursor to maintenance naltrexone treatment in heroin users: outcomes at 6 and 12 months.
    McGregor C; Ali R; White JM; Thomas P; Gowing L
    Drug Alcohol Depend; 2002 Sep; 68(1):5-14. PubMed ID: 12167548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute opioid withdrawal precipitated by ingestion of crushed embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature.
    Ruan X; Chen T; Gudin J; Couch JP; Chiravuri S
    J Opioid Manag; 2010; 6(4):300-3. PubMed ID: 20862910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Opioid detoxication under general anesthesia].
    Zemtsovski MJ; Trosko O; Schmidt H
    Ugeskr Laeger; 2002 Sep; 164(36):4165-9. PubMed ID: 12362827
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.